Please use this identifier to cite or link to this item:
|Title:||NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer||Authors:||Chiong, E.
|Issue Date:||Mar-2011||Citation:||Chiong, E., Kesavan, A., Mahendran, R., Chan, Y.H., Sng, J.H., Lim, Y.K., Kamaraj, R., Tan, T.M.C., Esuvaranathan, K. (2011-03). NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer. European Urology 59 (3) : 430-437. ScholarBank@NUS Repository. https://doi.org/10.1016/j.eururo.2010.11.031||Abstract:||Background: The natural resistance-associated macrophage protein 1 (NRAMP1) gene is associated with susceptibility to Mycobacterium tuberculosis in humans and to bacillus Calmette-Guérin (BCG) in mice. The detoxification enzyme, human glutathione peroxidase 1 (hGPX1), is associated with recurrence of bladder cancer (BCa). Objective: To determine whether NRAMP1 and hGPX1 gene polymorphisms correlate with response to BCG immunotherapy for non-muscle-invasive BCa (NMIBC). Design, setting, and participants: DNA was obtained from the peripheral blood of 99 NMIBC patients who were prospectively randomized to receive postresection intravesical BCG (81 mg [n = 50] or 27 mg [n = 19]) or BCG (27 mg) with interferon alpha (IFN-α; n = 30). The median follow-up time was 60 mo. Intervention: Intravesical BCG or BCG-IFN-α. Measurements: Restriction fragment length polymorphism (RFLP) analysis was performed to identify polymorphisms in the NRAMP1 promoter region (GT repeat number) and at position 543 (aspartate [D] and/or asparagine [N] expression) within the NRAMP1 protein (D543N) and position 198 (proline and/or leucine expression) within the hGPX1 protein (Pro198Leu). Data were analyzed using χ2 analysis, multivariate analysis, and Kaplan-Meier curves. Results and limitations: On univariate analysis, the NRAMP1 D543N G:G genotype had decreased cancer-specific survival (CSS; p = 0.036). The hGPX1 CT genotype (Pro-Leu) had decreased recurrence time (p = 0.03) after BCG therapy. On multivariate analysis, patients with the NRAMP1 D543N G:G genotype and allele 3 (GT)n polymorphism had decreased recurrence time (p = 0.014 and p = 0.03) after BCG therapy. The limitation of this study was its small sample size. Conclusions: Polymorphisms of the NRAMP1 and hGPX1 genes may be associated with recurrence of BCa after BCG immunotherapy. © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.||Source Title:||European Urology||URI:||http://scholarbank.nus.edu.sg/handle/10635/109495||ISSN:||03022838||DOI:||10.1016/j.eururo.2010.11.031|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2020
WEB OF SCIENCETM
checked on Feb 7, 2020
checked on Feb 15, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.